Breast Medical Oncologist Clinical Trial Leader. University of Maryland, Greenebaum Cancer Center. Tweets= own opinion
Boston, MA
Joined June 2016
- Tweets3.1K
- Following1.5K
- Followers5.9K
- Likes11.7K
Dr Sarah Sammons retweeted
Voting in the ASCO Election is open now until December 2! Meet the candidate for President-Elect, @teekayowo MD, PhD, FASCO.
Learn more about Dr. Owonikoko and make your voice heard: bit.ly/4zi4KWm
Dr Sarah Sammons retweeted
Proud to support Dr. Taofeek Owonikoko for #ASCO President.
As my fearless leader at @UMGCCC , I see daily how he leads: with generosity, vision, fairness and a deep commitment to patients and the people who care for them.
ASCO members, please vote! #ASCO @UMmedschool @UMBaltimore @UMGCCC
Voting in the ASCO Election is open now until December 2! Meet the candidate for President-Elect, @teekayowo MD, PhD, FASCO.
Learn more about Dr. Owonikoko and make your voice heard: bit.ly/4zi4KWm
Dr Sarah Sammons retweeted
Help shape the future of @ASCO by voting in the ASCO election. My fellow candidates and I encourage you to visit asco.org/election
to learn more about our personal interests in running, then place your vote!
Proud to support Dr. Taofeek Owonikoko for #ASCO President.
As my fearless leader at @UMGCCC , I see daily how he leads: with generosity, vision, fairness and a deep commitment to patients and the people who care for them.
ASCO members, please vote! #ASCO @UMmedschool @UMBaltimore @UMGCCC
Voting in the ASCO Election is open now until December 2! Meet the candidate for President-Elect, @teekayowo MD, PhD, FASCO.
Learn more about Dr. Owonikoko and make your voice heard: bit.ly/4zi4KWm
Dr Sarah Sammons retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Nominating Committee. Visit asco.org/election to learn more about the candidates and place your vote!
Dr Sarah Sammons retweeted
I am proud to support @DrDawnHershman @columbiacancer for @ASCO Board of Directors. Her research has transformed how we care for patients with breast cancer, and she is Co-Chair of @SWOG. She is the most generous mentor I know and will represent us well. Please vote. Vision and video here - asco.org/about-asco/asco-ove…
Dr Sarah Sammons retweeted
Addition of Tucatinib to Trastuzumab/Pertuzumab After Local Therapy for Isolated icPD in HER2+mBC: Primary Results of the Ph2 BRIDGET Trial in @ESMO_Open presented at #ESMO2026. Median icPFS not reached (mFUP 19.6 months), 46/47 pts alive @ data cut-off. esmoopen.com/article/S2059-7…
Dr Sarah Sammons retweeted
#ESMO26 | BRIDGET
A clinically valuable study addressing a real treatment dilemma in HER2+ breast cancer. Adding tucatinib after local therapy for isolated brain progression achieved 18-month intracranial PFS of 59% and extracranial PFS of 98%.
Durable CNS control while maintaining an effective systemic regimen—a thoughtful strategy with compelling results. Congratulations to the investigators! @drsarahsam 👏
Tucatinib added to HP is a nice option for 1L low volume brain only disease after local therapy.
Particularly in patients with no extracranial disease where the toxicity of ADC is not desired.
#ESMO26
📌 BRIDGET: A phase II trial of tucatinib added to trastuzumab/pertuzumab or ado-trastuzumab emtansine after isolated intracranial progression in patients with advanced HER2-positive breast cancer
✨@drsarahsam
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
Dr Sarah Sammons retweeted
Very exciting to have Bridget published simultaneously in @ESMO_Open available open access on line!! @drsarahsam @laura_huppert @PTarantinoMD @OncoAlert
Dr Sarah Sammons retweeted
📌 BRIDGET: A phase II trial of tucatinib added to trastuzumab/pertuzumab or ado-trastuzumab emtansine after isolated intracranial progression in patients with advanced HER2-positive breast cancer
✨@drsarahsam
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
Dr Sarah Sammons retweeted
Switching ADC target does not work. Switching payload does.
Among 60 TOPO1-ADC-pretreated patients with MBC, using a microtubule (MMAE) ADC led to 30% ORR and DoR of 8.8 mo. #ESMO26 #ESMOAmbassadors
These results are absolutely astounding.
This should give us enthusiasm to study more IT targeted therapies.
I do need to understand in this trial who got concurrent TDxd as this is likely contributing to results.
#ESMO26
IT trastuzumab and pertuzumab for HER2+ LMD
(Pts could continue treatment with HER2-directed systemic therapy)
@OncoAlert #ESMO26
Dr Sarah Sammons retweeted
Starting in 2h, Rapid Oral Breast Advanced session, featuring a prospective trial of ADC sequencing (SWITCH), brain mets analysis from DB09, BRIDGET, MRD to predict exceptional response, our CHARISMA translational study, discussions by @LoiSher #PedramRazavi & more! #ESMO26
Dr Sarah Sammons retweeted
Overall survival matters, but it’s not the ONLY measure of meaningful treatment benefit! For people living with #MBC, delaying progression may mean more time feeling well, maintaining independence & living life. Keeping cancer under control matters, even when it doesn’t mean living longer! #bcsm
When OS Is Not Enough: The Emerging Need for Context-Sensitive Endpoint Frameworks in Oncology in @ESMO_Open presented at #ESMO2026. Context-sensitive frameworks are needed when OS is immature/confounded/not demonstrable with RTC. esmoopen.com/article/S2059-7…
